[Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection].
OBJECTIVE
As a second-line treatment for H. pylori eradication in the case of first-line OAC (omeprazole, amoxicillin, clarithromycin) treatment failure, a minimum of one-week OBMT quadruple therapy composed of omeprazole, bismuth, metronidazole, tetracycline has been recommended in European countries and one or two weeks in USA. In Korea, one-week OBMT quadruple therapy is recommended for the case of first-line OAC treatment failure. Because H. pylori eradication rate of one-week OBMT therapy in Korea is about 80%, the eradication rate of one week therapy is not satisfactory. We analyzed the effect of two-week second-line OBMT therapy.


METHODS
Between June 2002 and June 2003, 107 patients who were H. pylori positive (44 males and 63 females: mean age 51.8 years) after primary eradication therapy received two-week OBMT therapy. Four weeks after completion of therapy, 13C-urea breath test was performed to detect H. pylori.


RESULTS
After two weeks of OBMT therapy, eradication was achieved in 103 of 107 patients (96.3%) and in 68 of 71 peptic ulcer patients (95.8%).


CONCLUSIONS
Two-week OBMT therapy should be considered as a retreatment regimen with the eradication rate more than 90%.
Park
Sung Chul
SC
Department of Internal Medicine, Institute of Digestive Disease and Nutrition, Korea University College of Medicine, Sungbuk-gu, Seoul.
Chun
Hoon Jai
HJ
Jung
Sung Woo
SW
Keum
Bora
B
Han
Woo Sik
WS
Choung
Rok Son
RS
Kim
Yong Sik
YS
Jeen
Yoon Tae
YT
Lee
Hong Sik
HS
Um
Soon Ho
SH
Lee
Sang Woo
SW
Choi
Jai Hyun
JH
Kim
Chang Duck
CD
Ryu
Ho Sang
HS
Hyun
Jin Hai
JH
D000328:Adult; D000863:Antacids / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D001729:Bismuth / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage; D019233:Retreatment; D013752:Tetracycline / Q000008:administration & dosage
D000863:Antacids; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D008795:Metronidazole; D013752:Tetracycline; D009853:Omeprazole; D001729:Bismuth